Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Clin Infect Dis. 2015 Oct 20;62(3):383–391. doi: 10.1093/cid/civ884

Figure 2.

Figure 2

A, Proportion of human immunodeficiency virus (HIV)-infected participants who seroconverted to at least 1 or all of the 3 vaccine strains at 1 month postvaccination, stratified by CD4 count (cells/µL) and vaccine type. B, Proportion of HIV-infected participants with seroprotection to at least 1 or all 3 of the vaccine strains at 1 month postvaccination, stratified by CD4 cell count and vaccine type.